Abstract
ObjectiveAlthough immune checkpoint blockade (ICB) therapy represents a bright spot in antitumor immunotherapy, its clinical benefits in colorectal cancer (CRC) are limited. Therefore, a new target for mediating CRC immunosuppression...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have